Taking an antibiotic following unprotected sex can drastically reduce the risk of getting three sexually transmitted diseases (STDs) of bacterial origin in people at high risk, according to a clinical study revealed on Wednesday. These findings were presented at the International AIDS Conference in Montreal, Canada, where they were hailed as a milestone.
“This might lead to changing the clinical guidelines,” said Steven Deeks, AIDS specialist at the University of California-San Francisco (UCSF) and who did not participate in the study. Taking doxycycline reduced rates of gonorrhea and chlamydia infections among men who have sex with men by more than 60%, and also appeared to be highly effective once morest syphilis — but it is not There weren’t enough cases for these latest results to be statistically significant.
The drug was so effective that researchers stopped clinical trials sooner than expected. The publication of this study comes at a time when infection rates for these diseases are on the rise, especially among men who have sex with men, among whom the use of condoms has declined since the generalization of PrEP (pre -exposure), an effective preventive treatment once morest infection with the AIDS virus, HIV.
A previous clinical trial conducted by French researchers had demonstrated the effectiveness of doxycycline as post-exposure prophylaxis (PEP) once morest syphilis and chlamydia, but not once morest gonorrhea. This new study was conducted among approximately 500 people, mainly men with homosexual relationships, in San Francisco and Seattle. Some were on PrEP treatment for HIV, others were carriers of this virus.
Taking the antibiotic reduced the incidence of these STDs by 62% in participants with HIV
Within each of these two groups, regarding two-thirds of the participants received doxycycline while the others did not. A follow-up was ensured by collecting the results every three months. The treatment was given within three days following exposure and for as long as necessary depending on the frequency of sexual intercourse.
Taking the antibiotic reduced the incidence of these STDs by 62% among participants with HIV, and by 66% among those taking PrEP. Side effects were mild and participants generally followed the treatment diligently. “We now have two studies that support the use of doxycycline as a PEP in men who have sex with men,” lead author Annie Luetkemeyer of UCSF said Wednesday at a conference. Press.
“I really believe that we need to think very seriously regarding rolling out (this treatment) and how to incorporate it into the guidelines,” to advise its use. However, she pointed out that the available data supported the use of this treatment in a targeted manner among groups at high risk of STDs, but not for everyone. Further studies will need to look at the potential impact on the resistance of these STDs or other bacteria to antibiotics, the authors added, as well as the potentially disruptive consequences on gut flora.
